🔬 Breakthrough Advancement in Clinical Research for the Treatment of Keratoconus 🔬
We are excited to announce the publication of the ARGO clinical trial validating theranostics technology for the precision, predictive and personalized treatment of keratoconus.
The multicenter clinical study ARGO, conducted in three major universities in Italy (Florence, Messina and Catanzaro), has shown that theranostic-guided corneal cross-linking offers a revolutionary approach to halt the progression of keratoconus by predicting the outcome at 1 year after treatment with 95% accuracy and 91% accuracy. This clinical validation marks a significant milestone in advancing the definitive cure of keratoconus.
For further details, read the full study in the most prestigious scientific journal in Ophthalmology (available for free download until September 5, 2024).
With the validation of theranostics for the definitive cure of keratoconus, Regensight marks the first milestone of its development plan that introduces for the first time in the world a transformative technology for the correction of the most disabling visual disorders at all ages.